Targeting Tumor Microenvironment by Small-Molecule Inhibitors.

Area of Science:

• Oncology
• Pharmacology

Background:

• The tumor microenvironment (TME) is characterized by hypoxia, acidity, and immune cell infiltration, significantly influencing tumor progression and treatment resistance.
• Conventional chemotherapy often struggles with penetration and accessibility to cancer cells within the TME.
• Targeting the TME presents a viable strategy for improving solid tumor treatment outcomes.

Purpose of the Study:

• To review recent advancements in small-molecule inhibitors designed to target the TME for cancer therapy.
• To highlight strategies focusing on TME-specific targeting or drug delivery systems.

Main Methods:

• Literature review of recent research on small-molecule inhibitors and TME-targeting strategies.
• Analysis of studies focusing on drug penetration, accessibility, and TME component targeting.

Main Results:

• Small-molecule inhibitors demonstrate superior penetration and accessibility compared to conventional chemotherapies.
• Emerging strategies involve developing inhibitors that specifically target TME components or utilize TME-responsive drug delivery systems.

Conclusions:

• Small-molecule inhibitors targeting the TME represent a significant advancement in cancer treatment.
• Further research into TME-specific therapies holds great potential for overcoming treatment resistance and improving patient outcomes.